This refresh
Data-driven refresh August 21, 2026. The Top Picks are the Bull Rankings quality-growth screen — strong, growing businesses with durable returns at a fair price (PEG / EV-EBIT vs sector, ROIC, free cash flow). Scanned every US-listed common stock on NYSE, NASDAQ, NYSE American, and NYSE Arca (5,245 tickers); 1,673 scored on the quality-growth model (financials route to a separate card). Fundamentals from Yahoo Finance quoteSummary reconciled with as-reported SEC EDGAR filings; narrative authored by Groq (with Gemini and data-driven fallbacks).
Top Picks — quality compounders at a fair price
1. ADBE — Adobe Inc. · score 89.4
Software - Application · price $272.22 · 1Y $270.61 · 5Y $396.19 · 10Y $587.73
FCF $10.3b A- · Rev +11.5% B · D/E 0.61 C+ · P/E 15.6x A- · PEG 0.66 A-
Why now. Adobe’s Digital Media subscription engine is the cash‑cow that fuels compounding, delivering 11.5% YoY revenue growth, $10.3 B of free cash flow, and a razor‑thin P/E of 15.6x that leaves ample headroom for earnings expansion; coupled with our model’s Quality score of 92, the business’s high‑margin recurring model should keep the growth engine humming for years, making the next 12‑months a decisive period to lock in the upside.
Moat. The Creative Cloud and Document Cloud platforms lock in photographers, video editors, marketers and enterprises on multi‑year licenses, creating switching costs that are hard to replicate; this sticky subscription base underpins the 62.8% ROE, which stems from pricing power in a category‑lead position where Adobe can command premium rates for its integrated workflow suite.
Risk. A 1.4 beta and a debt‑to‑equity of 0.61 expose Adobe to market volatility and leverage risk, while the Bull Rankings model’s weakest pillar—Growth (86)—signals that the market may be over‑relying on a modest 1% FCF growth assumption; a slowdown in subscription renewals or margin compression would push the stock toward its 52‑week low of $190.12, confirming the bear case.
Horizon. 1-3 yr $270.61 (analyst consensus (n=34)) — fundamentals + valuation re-rating. 5 yr $396.19 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $587.73 if current growth sustains into durable earnings power.
2. HRMY — Harmony Biosciences Holdings, Inc. · score 88.7
Biotechnology · price $38.07 · 1Y $46.10 · 5Y $67.50 · 10Y $100.12
FCF $355m C · Rev +24.3% A- · D/E 0.16 B+ · P/E 12.3x A · PEG 0.44 A
Why now. Harmony Biosciences presents a compelling growth story, driven by the continued expansion of its flagship narcolepsy treatment, WAKIX, and a promising pipeline targeting rare neurological diseases like Prader-Willi Syndrome and Myotonic Dystrophy. Our model's strongest pillar for HRMY is Value at 95, indicating significant undervaluation, especially given its robust 24.3% FY YoY revenue growth and a remarkably low 12.3 P/E TTM. The market is pricing in a pessimistic ~-18%/yr free-cash-flow growth for the next decade, a stark contrast to its current performance and pipeline potential, suggesting substantial upside as these growth drivers materialize.
Moat. Harmony Biosciences' competitive edge stems from WAKIX (pitolisant), a molecule with a novel mechanism of action, addressing excessive daytime sleepiness in narcolepsy, which provides a differentiated offering in a specialized market. The company's focus on developing therapies for rare neurological diseases, including Pitolisant in Phase 3 for Prader-Willi Syndrome, further insulates it from broader market competition by targeting underserved patient populations. Our model signals durable high returns, reinforcing the long-term sustainability of its specialized product portfolio and development strategy.
Risk. The primary bear case for Harmony Biosciences centers on its revenue concentration around WAKIX, leaving it vulnerable to potential new competitive entrants or unexpected safety concerns in the narcolepsy market. While the debt-to-equity ratio is low at 0.16, our model's weakest pillar is Quality at 80, reflecting the inherent risks of a commercial-stage pharmaceutical company heavily reliant on a single flagship product and the binary outcomes of its pipeline candidates for conditions like Prader-Willi Syndrome. A significant setback in the ongoing Phase 3 trial for Pitolisant in PWS or a material deceleration in WAKIX's revenue growth would confirm the bear thesis.
Horizon. 1-3 yr $46.10 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $67.50 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $100.12 if current growth sustains into durable earnings power.
3. DLO — DLocal Limited · score 88.6
Software - Infrastructure · price $14.34 · 1Y $18.40 · 5Y $26.94 · 10Y $39.96
FCF $413m C · Rev +46.6% A · D/E 0.12 B+ · P/E 21.1x B+ · PEG 0.67 A-
Why now. DLocal’s pay‑in platform for global merchants is exploding, delivering 46.6% YoY revenue growth while converting that into a razor‑thin PEG of 0.67 and a healthy ROE of 34.6%—the exact compounding engine our model flags as its strongest Growth pillar. With a Quality‑Growth score of 88.6, the business’s high returns are already baked in, but the still‑under‑priced Value pillar leaves upside room. The thesis hinges on sustaining this payment‑processing tailwind across e‑commerce, streaming and ride‑hailing, keeping the growth engine humming.
Moat. DLocal’s moat lives in its end‑to‑end pay‑in and pay‑out suite that locks merchants into a single integration for hundreds of local cards, bank transfers and alternative payment methods, creating high switching costs and network effects. The 34.6% ROE stems from pricing power as the only gateway for cross‑border transactions in emerging markets, a position hard for new entrants to replicate quickly.
Risk. The bear case centers on the premium valuation: a forward P/E of 21.1 is high for a still‑emerging fintech, and the Bull Rankings model’s reverse DCF shows the current price implies a -8% annual free‑cash‑flow growth over the next decade—far below the 46.6% revenue surge, suggesting investors are already over‑optimistic. A slowdown in cross‑border e‑commerce or a pricing squeeze would push the P/E even higher and validate the overvaluation, snapping the upside.
Horizon. 1-3 yr $18.40 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $26.94 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $39.96 if current growth sustains into durable earnings power.
4. NBIX — Neurocrine Biosciences, Inc. · score 88
Drug Manufacturers - Specialty & Generic · price $152.93 · 1Y $211.57 · 5Y $309.76 · 10Y $459.51
FCF $870m C+ · Rev +34.4% A · D/E 0.12 B+ · P/E 22.4x B+ · PEG 0.46 A
Why now. NBIX is poised to double its earnings as INGREZZA expands its market share in tardive dyskinesia, driven by 34.4% revenue growth, a robust 20.9% profit margin, and a strong cash engine delivering $870m free cash flow. The combination of a high‑margin franchise and a pipeline of movement‑disorder candidates fuels a compounding engine that will keep growth accelerating. The thesis hinges on sustaining this premium earnings growth.
Moat. The moat rests on INGREZZA’s first‑in‑class status for tardive dyskinesia and limited therapeutic alternatives, giving Neurocrine pricing power that translates into a 19.1% ROE and a durable 20.9% profit margin**. This specialty focus, backed by FDA‑approved products and a pipeline targeting unmet neurological needs, creates high switching costs for neurologists and insurers.
Risk. The bear case centers on the reliance on a narrow product set; any adverse data or competitive entry could stall the 34.4% revenue growth trajectory, while the current P/E of 22.4 is premium for a specialty biotech and leaves little room for error. A miss on upcoming trial readouts or a slowdown in new‑patient uptake would push the stock back toward its 52‑week low of $122.14, confirming the downside.
Horizon. 1-3 yr $211.57 (analyst consensus (n=27)) — fundamentals + valuation re-rating. 5 yr $309.76 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $459.51 if current growth sustains into durable earnings power.
5. PGY — Pagaya Technologies Ltd. · score 86.2
Software - Infrastructure · price $20.24 · 1Y $29.20 · 5Y $42.75 · 10Y $63.42
FCF $252m C · Rev +25.6% A- · D/E 1.34 C · P/E 14.4x A- · PEG 0.04 A
Why now. Pagaya Technologies is a compelling growth opportunity, significantly undervalued by the market given its potent AI-powered platform for financial services. The company's "Decline Monetization" product is driving robust expansion, evidenced by 25.6% FY YoY revenue growth and a healthy 9.1% profit margin. With a remarkably low 0.04 PEG ratio and a P/E of 14.4, our Bull Rankings model correctly identifies Value (99/100) as PGY's strongest pillar, signaling deep pessimism is already priced in. The crux is that the market is failing to appreciate the compounding effect of its technology in monetizing previously rejected loan applications.
Moat. Pagaya's durable edge stems from its proprietary data science and AI-powered technology, which is deeply embedded in the loan application processes of its financial services partners through products like "Decline Monetization" and "Dual Look." This creates significant switching costs and a powerful network effect: as more partners use Pagaya's network to evaluate loan applications, the AI models gain more data, enhancing their predictive accuracy and value proposition. This continuous feedback loop, combined with its specialized focus on approving customers partners would otherwise decline, makes its solution difficult for competitors to replicate quickly.
Risk. The primary risk for Pagaya lies in its high sensitivity to economic cycles and potential shareholder dilution. With a beta of 5.37, PGY is highly susceptible to market downturns, which could severely impact its financial services partners and the institutional investors funding its network. Our Bull Rankings model flags Quality (70/100) as PGY's weakest pillar, reflecting concerns about its business consistency, further compounded by a debt-to-equity ratio of 1.34 and the model's caution signal of "Diluting shareholders." A concrete signal confirming the bear case would be a sustained decline in the volume of loan applications processed through its network or a significant increase in its debt burden without corresponding asset growth.
Horizon. 1-3 yr $29.20 (analyst consensus (n=10)) — fundamentals + valuation re-rating. 5 yr $42.75 at ~16% CAGR — compounding case rests on the competitive position widening. 10 yr $63.42 if current growth sustains into durable earnings power.
6. NVDA — NVIDIA Corporation · score 85.9
Semiconductors · price $216.85 · 1Y $304.12 · 5Y $445.26 · 10Y $660.52
FCF $119.1b A · Rev +70.7% A · D/E 0.07 A- · P/E 33.2x B · PEG 0.60 A-
Why now. NVIDIA’s AI‑driven Compute & Networking platform is the engine of unstoppable compounding, as data‑center customers double‑down on its accelerated GPUs. The business is delivering 70.7% YoY revenue growth, $119.1 B of free‑cash‑flow and an eye‑popping 81.7% ROE, all while trading at a modest PE of 33.2. The bull case rests on the continuation of this AI spend cycle, which will keep cash generation and earnings expanding at a rate that outpaces peers.
Moat. NVIDIA’s moat lives in its proprietary GPU architecture that powers the world’s largest AI supercomputers, creating a switching cost that rivals can’t match without years of R&D. This pricing power fuels the 81.7% ROE, as enterprise and cloud customers pay a premium for performance that only NVIDIA’s Compute & Networking segment can deliver.
Risk. The stock’s lofty beta of 2.21 and a PE of 33.2 imply the market is already pricing in aggressive growth; a slowdown in AI spend or a margin squeeze would expose that optimism. If the reverse‑DCF implied 50% annual FCF growth proves unrealistic, the valuation collapses, and the next earnings miss would trigger a sharp sell‑off.
Horizon. 1-3 yr $304.12 (analyst consensus (n=58)) — fundamentals + valuation re-rating. 5 yr $445.26 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $660.52 if current growth sustains into durable earnings power.
7. GDDY — GoDaddy Inc. · score 85.4
Software - Infrastructure · price $98.19 · 1Y $104.80 · 5Y $153.44 · 10Y $227.61
FCF $1.7b C+ · Rev +7.4% B · D/E n/a · P/E 14.6x A- · PEG 0.68 A-
Why now. The bull case hinges on GoDaddy’s Applications & Commerce suite—especially the high‑margin Websites + Marketing and Managed WordPress tools—that is fueling a resilient 7.4% YoY revenue growth while delivering a robust 17.8% profit margin and a healthy $1.7B free‑cash‑flow. With a PEG of 0.68 and a PE of 14.6, the stock trades well below the implied -15%/yr FCF growth from our reverse DCF, meaning the market is already pricing in optimism; the real upside lies in compounding this cash flow through continued buybacks and expanding the A&C platform. The thesis rests on the ability of the A&C segment to keep compounding cash flow at a rate that outpaces the -15% model assumption.
Moat. GoDaddy’s moat derives from its integrated platform that bundles website building, e‑commerce, SEO, and design tools into a single subscription ecosystem, creating high switching costs for small‑business owners who rely on the seamless integration of Domains, Hosting, and Marketing services. This stickiness, combined with a massive installed base of over a million active sites, gives GoDaddy pricing power and a defensible position that competitors cannot replicate quickly without massive infrastructure investment.
Risk. The bear case centers on the modest growth pillar—our model scores Growth at only 75—highlighting that the 7.4% revenue expansion may decelerate as the market saturates and larger platforms lure customers away, while the current PE of 14.6, though reasonable, still reflects a premium for growth that could be eroded if margins compress below the 17.8% level. A slowdown in A&C adoption or a margin dip below 15% would validate the implied -15% FCF growth and could push the stock back toward its 52‑week low of $71.59. Confirmation would be a quarterly earnings miss on both revenue and margin.
Horizon. 1-3 yr $104.80 (analyst consensus (n=15)) — fundamentals + valuation re-rating. 5 yr $153.44 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $227.61 if current growth sustains into durable earnings power.
8. INTU — Intuit Inc. · score 85
Software - Application · price $361.87 · 1Y $446.02 · 5Y $653.02 · 10Y $968.70
FCF $7.8b B+ · Rev +15.1% B+ · D/E 0.33 B · P/E 22.1x B+ · PEG 0.94 B+
Why now. Intuit’s QuickBooks Online platform, now bolstered by Mailchimp’s marketing automation, is the engine of a self‑reinforcing growth loop that fuels small‑business adoption and upsell opportunities. The business is delivering 15.1% revenue growth YoY, while maintaining a healthy 21.9% profit margin and generating 22.2% ROE, all on a $99.0B market cap and a rising dividend. The thesis hinges on the ability of the QuickBooks‑Mailchimp combo to keep compounding cash flow at a rate that outpaces the modest -1% FCF growth implied by our reverse‑DCF.
Moat. The QuickBooks ecosystem locks SMBs into an integrated suite of accounting, payroll, payments and financing, creating high switching costs; once a customer adopts the platform, adding Mailchimp’s CRM deepens stickiness and enables pricing power that drives the 22.2% ROE. This cross‑sell advantage is hard for rivals to replicate quickly because it requires both a mature accounting stack and a proven marketing automation layer.
Risk. The market is pricing Intuit at a lofty 22.1× forward earnings, far above many software peers, and the reverse‑DCF suggests a -1% annual FCF growth assumption that would be disastrous if the 15.1% revenue expansion stalls. A slowdown in SMB spending or a successful encroachment by larger ERP players would compress margins and could push the stock back toward its 52‑week low of $252.84, confirming the bear case.
Horizon. 1-3 yr $446.02 (analyst consensus (n=33)) — fundamentals + valuation re-rating. 5 yr $653.02 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $968.70 if current growth sustains into durable earnings power.
9. DOCS — Doximity, Inc. · score 84.1
Health Information Services · price $25.94 · 1Y $29.39 · 5Y $43.03 · 10Y $63.83
FCF $306m C · Rev +11.2% B · D/E 0.01 A- · P/E 30.9x B · PEG 0.59 A-
Why now. Doximity's highly profitable digital platform for medical professionals is currently undervalued, with today's price implying only ~8%/yr free-cash-flow growth sustained for 10 years, which sits below its actual FY YoY revenue growth of 11.2%. This suggests pessimism is priced into a business that boasts a robust 25.5% profit margin and a remarkably low 0.01 debt-to-equity ratio. Our model's Quality-growth score of 84.1/100, with Quality as its strongest pillar (89/100), reinforces the view that the market is overlooking the compounding power of its integrated workflow tools and sponsored content revenue.
Moat. Doximity's durable edge stems from its powerful network effect among U.S. medical professionals, making its Doximity platform an indispensable hub for clinical content, peer updates, and HIPAA-compliant workflow tools like Ask and Scribe. This deep integration creates high switching costs and a captive audience, attracting pharmaceutical manufacturers and health systems for sponsored content, which underpins the company's strong 18.2% ROE. Our model's high Quality pillar score of 89/100 reflects this entrenched position and the difficulty for competitors to replicate such a trusted and widely adopted professional network.
Risk. The primary bear case for Doximity centers on its reliance on sponsored content from pharmaceutical manufacturers and health systems, which could be vulnerable to cyclical advertising budget cuts or increased competition for digital ad spend. With a P/E (TTM) of 30.9, the stock's valuation already prices in significant growth, making it susceptible to multiple contraction if revenue growth decelerates from the current 11.2%. Our model identifies Value as the weakest pillar (79/100), highlighting this valuation sensitivity; a sustained slowdown in platform engagement or a material decline in profit margins would confirm the bear thesis.
Horizon. 1-3 yr $29.39 (analyst consensus (n=18)) — fundamentals + valuation re-rating. 5 yr $43.03 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $63.83 if current growth sustains into durable earnings power.
10. CARG — CarGurus, Inc. Class A Common Stock · score 83.4
Auto & Truck Dealerships · price $36.89 · 1Y $41.50 · 5Y $60.76 · 10Y $90.13
FCF $315m C · Rev +13.9% B+ · D/E 0.70 B+ · P/E 19.0x B · PEG 1.08 B+
Why now. CarGurus’ Digital Deal platform is unlocking a new, high‑margin online purchase funnel, letting shoppers start financing and paperwork before stepping onto the lot. That engine is already powering a 13.9% YoY revenue growth and a rock‑solid 18.2% profit margin, while the balance sheet fuels a $315 m free‑cash‑flow run‑rate that underwrites aggressive buybacks. The thesis hinges on the Digital Deal’s ability to compound this cash‑flow and margin expansion as more dealers migrate to our subscription‑based, data‑rich marketplace.
Moat. The moat lives in CarGurus’ integrated dealer subscription and advertising suite, which locks a dense network of dealers into a single data‑driven marketplace. This creates switching costs for both dealers and shoppers, and the resulting pricing power drives an ROE of 66.6%, far above the sector norm, because dealers pay recurring fees for the traffic and lead quality that only CarGurus can deliver at scale.
Risk. The stock trades at a forward P/E of 19, a multiple that presumes sustained double‑digit growth; any slowdown—evidenced by the Bull Rankings model’s implied -2% FCF growth over ten years—would leave the valuation stretched. A debt‑to‑equity of 0.7 also signals rising leverage that could bite if the auto market contracts, and a beta of 1.17 adds volatility. A breach of the 19× P/E or a dip in margin would confirm the bear case and derail the upside.
Horizon. 1-3 yr $41.50 (analyst consensus (n=12)) — fundamentals + valuation re-rating. 5 yr $60.76 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $90.13 if current growth sustains into durable earnings power.
11. APP — AppLovin Corporation · score 83.3
Advertising Agencies · price $308.77 · 1Y $528.32 · 5Y $773.52 · 10Y $1,147
FCF $4.5b B · Rev +60.6% A · D/E 1.11 C+ · P/E 23.7x B · PEG 0.88 B+
Why now. AppLovin is a compounding growth story, leveraging its end-to-end AI-powered advertising solutions to capture significant market share. Our model's strongest pillar, Growth (96/100), is validated by the company's staggering 60.6% FY YoY revenue growth. With a PEG ratio of just 0.88, the market is currently undervaluing this trajectory, especially considering our reverse DCF implies only ~14%/yr free-cash-flow growth sustained for 10 years—a conservative estimate against its actual expansion. The crux of the thesis rests on the continued adoption and monetization of its integrated platform, including Axon Ads Manager and MAX, driving persistent high returns.
Moat. AppLovin's durable edge stems from its comprehensive, AI-powered advertising ecosystem, encompassing solutions like Axon Ads Manager, MAX, Adjust, and Wurl. This integrated offering creates high switching costs and network effects for businesses reliant on its platform for optimizing ad inventory and marketing efforts. The company's exceptional 64.6% profit margin and robust $4.5b in TTM free cash flow underscore the power of its proprietary AI and the deep integration of its solutions, which are difficult for competitors to replicate quickly.
Risk. Skeptics would point to AppLovin's extreme market sensitivity, evidenced by its 2.53 beta and the stock trading near its $303.17 52-week low, suggesting significant downside risk in a volatile market. The Bull Rankings model's weakest pillar, Value (67/100), implies that despite strong growth, the market remains cautious on its long-term valuation. A sustained deceleration in advertising spend, particularly impacting its core mobile and connected TV platforms like Wurl, would confirm the bear case, eroding its high profit margins and free cash flow generation.
Horizon. 1-3 yr $528.32 (analyst consensus (n=31)) — fundamentals + valuation re-rating. 5 yr $773.52 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $1,147 if current growth sustains into durable earnings power.
12. EPAM — EPAM Systems, Inc. · score 82
Information Technology Services · price $106.76 · 1Y $122.82 · 5Y $179.83 · 10Y $266.76
FCF $483m C · Rev +10.8% B · D/E 0.04 A- · P/E 14.5x A- · PEG 0.57 A-
Why now. EPAM’s digital platform engineering franchise is locked into the multi‑year cloud migration and AI modernization cycles of Fortune‑500 enterprises, delivering 10.8% revenue growth YoY while generating $483 m of free cash flow and trading at a modest PE 14.5×. Our Bull Rankings model gives the stock an 82/100 quality‑growth score, with Value as the strongest pillar and Quality as the weakest, underscoring that the market already rewards its cash‑rich balance sheet and buy‑back program. The thesis rests on the relentless compounding of high‑margin engineering contracts as enterprises double‑down on cloud and AI initiatives.
Moat. EPAM’s end‑to‑end engineering services—from requirements analysis to smart‑automation—create deep integration with client tech stacks, making migration to a rival provider costly and time‑consuming. Its low‑debt balance sheet (debt‑to‑equity 0.04) and ROE of 11.4% stem from pricing power in a niche where few firms can match its breadth of cloud, AI, and cybersecurity expertise, cementing a durable competitive edge.
Risk. The stock’s beta of 1.37 amplifies market swings, and the Bull Rankings model flags Quality as the weakest pillar (73), suggesting execution risk if EPAM cannot sustain its current margin of 7.2% amid intensifying competition from larger consulting firms. A slowdown in enterprise cloud spend that drags revenue growth below the 10.8% pace would validate the bear case and could push the price back toward its 52‑week low of $73.06.
Horizon. 1-3 yr $122.82 (analyst consensus (n=17)) — fundamentals + valuation re-rating. 5 yr $179.83 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $266.76 if current growth sustains into durable earnings power.
13. LRN — Stride, Inc. · score 81.9
Education & Training Services · price $84.07 · 1Y $96.68 · 5Y $141.55 · 10Y $209.98
FCF $433m C · Rev +4.7% C+ · D/E 0.33 A- · P/E 11.8x A · PEG 0.49 A
Why now. Stride’s integrated state‑customized learning platform for software engineering and healthcare curricula is a cash‑generating engine that can be scaled without heavy capex, delivering a 13.4% profit margin, a 20.7% ROE and $433 m of free cash flow on a $3.5 b market cap. The Bull Rankings model scores the stock 81.9/100, with Value as its strongest pillar, confirming that the market is pricing the business far below its sustainable cash‑flow generation. The thesis hinges on the platform’s ability to keep expanding state contracts while the balance sheet remains low‑risk (debt‑to‑equity 0.33).
Moat. The platform’s single‑sign‑on, end‑to‑end LMS and student‑information system lock districts into a unified tech stack that is costly to replace, creating high switching costs for state education agencies. This lock‑in fuels the 20.7% ROE by allowing Stride to command pricing power on its proprietary curriculum and analytics suite, a moat that competitors can’t replicate quickly.
Risk. Revenue is only growing 4.7% YoY and the model’s Growth pillar is the weakest (67), meaning the market’s 11.8 × P/E and 0.49 PEG are built on an optimistic –11% annual FCF growth assumption from the reverse DCF. If state funding tightens or the platform fails to win new contracts, the low growth will expose the over‑priced valuation; a sustained slowdown below 4% would trigger a price correction toward the 52‑week low of $60.61.
Horizon. 1-3 yr $96.68 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $141.55 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $209.98 if current growth sustains into durable earnings power.
14. EXLS — ExlService Holdings, Inc. · score 81.8
Information Technology Services · price $37.05 · 1Y $44.38 · 5Y $64.97 · 10Y $96.38
FCF $297m C · Rev +13.4% B+ · D/E 0.57 C+ · P/E 23.4x B+ · PEG 1.10 B+
Why now. EXLS is poised to dominate AI‑driven claims and underwriting automation for insurers, a segment where it already runs the largest digital operations platform in North America. The business is growing revenue at 13.4% YoY, converting that into a robust 11.7% profit margin and a stellar ROE of 32.3%, while free cash flow hits $297 m on a $5.6 b market cap. Our Bull Rankings model gives EXLS an 81.8/100 quality‑growth score, with Growth as the strongest pillar, confirming that the compounding engine is real and will persist as insurers deepen AI adoption.
Moat. EXLS’s moat stems from its end‑to‑end AI platform that locks insurers into a data‑rich ecosystem covering claims management, policy servicing and actuarial analytics, creating high switching costs and network effects. The 32.3% ROE reflects pricing power earned from being the preferred provider for large insurance carriers across the U.S., U.K. and Europe, where its integrated solutions reduce operating costs and improve loss ratios—advantages a new entrant cannot replicate quickly.
Risk. The bear case focuses on the premium valuation: a forward P/E of 23.4 is above the sector median, and the Bull Rankings model’s reverse DCF assumes only ~5% free‑cash‑flow growth for the next decade—well below the current 13.4% revenue growth, implying that any slowdown or margin compression would expose the stock to a steep correction. A breach of the 52‑week low at $24.85 would signal that the market is re‑pricing this optimism.
Horizon. 1-3 yr $44.38 (analyst consensus (n=8)) — fundamentals + valuation re-rating. 5 yr $64.97 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $96.38 if current growth sustains into durable earnings power.
15. FISV — Fiserv, Inc. · score 81.4
Sector n/a · price $51.38 · 1Y $62.18 · 5Y $91.04 · 10Y $135.05
FCF $3.9b B · Rev +9.3% B · D/E n/a · P/E 9.8x A- · PEG 0.78 A-
Why now. Fiserv presents a compelling value opportunity disguised as a growth play, with our model's strongest pillar being Value (90/100), signaling deep undervaluation relative to its peers. The market's current price of $51.38 implies a ~-15%/yr free-cash-flow growth sustained for 10 years by our reverse DCF, a stark contrast to its actual 9.3% FY YoY revenue growth and robust $3.9b TTM free cash flow. This extreme pessimism, coupled with a low 9.8 P/E TTM, suggests a significant re-rating potential as the market recognizes its cash-generating power.
Moat. Fiserv's competitive advantage stems from the high switching costs inherent in its integrated financial technology solutions, which are deeply embedded into client operations. Once banks and merchants integrate Fiserv's payment processing and core banking platforms, the operational disruption and cost of switching to a competitor create a durable barrier. This sticky customer base underpins the company's consistent free cash flow generation and its 10.4% ROE.
Risk. Skeptics would point to the company's recent underperformance, with the stock trading near its $47.04 52-week low, far from its $140.19 52-week high, reflecting concerns about its long-term growth trajectory in a competitive fintech landscape. Our model's weakest pillar, Quality (76/100), suggests that while valuation is strong, the underlying business quality relative to sector peers could be a concern, potentially hindering sustained margin expansion beyond the current 17.3% profit margin. A definitive break in the bull thesis would be a sustained deceleration in revenue growth below the current 9.3%, indicating a loss of market share or pricing power.
Horizon. 1-3 yr $62.18 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $91.04 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $135.05 if current growth sustains into durable earnings power.
16. ADMA — ADMA Biologics, Inc. · score 81.3
Biotechnology · price $9.76 · 1Y $17.00 · 5Y $24.89 · 10Y $36.92
FCF $116m C · Rev +8.0% B · D/E 1.11 C · P/E 13.9x A- · PEG 0.60 A-
Why now. ADMA’s market‑leading IVIG franchise—anchored by BIVIGAM and ASCENIV—captures a growing U.S. immune‑deficiency market, driving a 33% profit margin and a 41.4% ROE. The business is scaling revenue at 8% YoY while trading at a modest PE of 14.1x and a sub‑1.0 PEG of 0.6, meaning earnings are already outpacing cash flow. Our Bull Rankings model awards ADMA a Quality‑growth score of 81.3, with Quality as its strongest pillar, underscoring the durable cash‑generating power that fuels the compounding thesis.
Moat. ADMA controls the entire plasma‑to‑product pipeline through its ADMA BioManufacturing and Plasma Collection Centers, creating high switching costs for hospitals that rely on its specialty IVIGs. This vertical integration, combined with pricing power in a niche therapeutic class, fuels the extraordinary 41.4% ROE—a return hard for generic competitors to replicate quickly.
Risk. The company’s leverage sits at a Debt‑to‑Equity of 1.11, and any tightening of plasma supply or regulatory headwinds could compress margins and stall the 8% revenue growth. Moreover, the Bull Rankings model flags a Growth pillar weakness, suggesting the 4% free‑cash‑flow growth implied by the reverse‑DCF may be optimistic if execution falters. A sustained rise in collection costs or a loss of market share to newer biologics would confirm the bear case.
Horizon. 1-3 yr $17.00 (analyst consensus (n=5)) — fundamentals + valuation re-rating. 5 yr $24.89 at ~20% CAGR — compounding case rests on the competitive position widening. 10 yr $36.92 if current growth sustains into durable earnings power.
17. RMD — ResMed Inc. · score 81
Medical Instruments & Supplies · price $228.44 · 1Y $245.50 · 5Y $359.44 · 10Y $533.20
FCF $1.6b C+ · Rev +9.9% B · D/E 0.13 B+ · P/E 21.9x B+ · PEG 1.34 B
Why now. ResMed’s AirView cloud platform, paired with its portable diagnostic devices like ApneaLink Air and NightOwl, locks in hospitals and home‑care providers into a data‑rich ecosystem that fuels recurring revenue, and the business is growing revenue at 9.9% YoY while delivering a 26.9% profit margin and a 23.1% ROE. The Bull Rankings model scores Quality at 81/100 – the strongest pillar – confirming that the franchise’s high returns are sustainable, and the 5% implied free‑cash‑flow growth in our reverse‑DCF is comfortably below the actual revenue growth, leaving upside room. The thesis hinges on continued expansion of cloud‑connected sleep solutions driving compounding earnings.
Moat. The AirView platform creates a high‑switching‑cost network for clinicians who rely on real‑time sleep data, while ResMed’s patented sensor technology in devices such as ApneaLink Air secures pricing power that underpins its 23.1% ROE. This cloud‑device integration locks in long‑term contracts with sleep clinics and home‑care providers, a moat that competitors cannot replicate quickly.
Risk. The market is pricing ResMed at a forward P/E of 21.9, which is lofty for a company whose revenue growth is only 9.9% YoY and whose reverse‑DCF assumes just 5% FCF growth – a mismatch that suggests optimism is already baked in; any slowdown in device adoption or a shift to lower‑margin tele‑health models would compress margins and validate a lower valuation. A breach of the 5% FCF growth assumption would trigger a sell‑off and invalidate the bull case.
Horizon. 1-3 yr $245.50 (analyst consensus (n=16)) — fundamentals + valuation re-rating. 5 yr $359.44 at ~9% CAGR — compounding case rests on the competitive position widening. 10 yr $533.20 if current growth sustains into durable earnings power.
18. PRDO — Perdoceo Education Corporation · score 80.1
Education & Training Services · price $32.48 · 1Y $37.35 · 5Y $54.69 · 10Y $81.12
FCF $221m C · Rev +11.7% B · D/E 0.11 A- · P/E 11.8x A · PEG 0.70 A-
Why now. PRDO is a compounder riding the secular tailwind of healthcare and tech education demand, with 20.6% profit margins and $221m in TTM free cash flow funding buybacks and dividends. The CTU segment’s career-focused programs in nursing and cybersecurity are sticky: students return for stackable credentials in high-demand fields, and 11.7% revenue growth proves the model scales without discounting. The crux is execution: management’s capital allocation discipline turns every dollar of FCF into shareholder value, not reinvestment into low-return growth.
Moat. The moat is built on regulatory barriers and brand concentration in niche, high-ROI degrees. USAHS’s dominance in occupational therapy (top 3 in the U.S.) creates pricing power: ROE of 17.1% reflects pricing power from category leadership in a credentialed profession where competitors can’t easily replicate clinical partnerships or accreditation. CTU’s cybersecurity and nursing programs benefit from network effects: employers recruit from a single, trusted pipeline, and alumni referrals reduce CAC. Competitors can’t replicate these relationships in under 2-3 years.
Risk. The bear case is that PRDO’s P/E of 11.8x assumes growth that isn’t guaranteed: if enrollment in USAHS’s occupational therapy programs slows due to state licensing changes or CTU’s cybersecurity pipeline saturates, revenue growth could decelerate below 8%. The stock’s valuation already embeds a reverse-DCF implied -13%/yr FCF growth for a decade — a collapse in demand would break the bull thesis. The signal to sell is a 2-consecutive-quarter decline in new student starts at USAHS.
Horizon. 1-3 yr $37.35 (structural (no analyst coverage)) — fundamentals + valuation re-rating. 5 yr $54.69 at ~11% CAGR — compounding case rests on the competitive position widening. 10 yr $81.12 if current growth sustains into durable earnings power.
19. DECK — Deckers Outdoor Corporation · score 79.7
Footwear & Accessories · price $88.86 · 1Y $122.81 · 5Y $179.81 · 10Y $266.73
FCF $1.1b C+ · Rev +7.9% B · D/E 0.21 A- · P/E 12.6x A- · PEG 1.12 B+
Why now. The HOKA performance‑running franchise is now the engine of Deckers’ growth, delivering 7.9% YoY revenue expansion, 18.4% profit margin and a staggering 44.1% ROE that fuels a $1.1B free‑cash‑flow base. Coupled with an aggressive share‑buyback program, the business compounds earnings at a rate that outpaces peers, making the current price a launchpad for upside.
Moat. Deckers locks in pricing power through HOKA’s proprietary cushioning technology and UGG’s premium‑leather heritage, allowing it to command margins that drive a 44% ROE—far above the sector average. Its direct‑to‑consumer and global retail network locks in repeat purchases from lifestyle‑focused consumers, creating a distribution moat that rivals can’t replicate quickly.
Risk. The Bull Rankings model implies a -2% annual free‑cash‑flow growth rate, a stark contrast to the actual 7.9% revenue growth, meaning the market is already pricing in optimistic performance; a slowdown in premium footwear demand or margin erosion would force the stock toward its 52‑week low of $78.91. A breach of the implied growth assumption would validate the bear case.
Horizon. 1-3 yr $122.81 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $179.81 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $266.73 if current growth sustains into durable earnings power.
20. GMED — Globus Medical, Inc. · score 79.2
Medical Devices · price $85.67 · 1Y $103.23 · 5Y $151.14 · 10Y $224.21
FCF $756m C+ · Rev +19.7% B+ · D/E 0.02 A- · P/E 21.9x B+ · PEG 1.49 B
Why now. Globus Medical’s spine‑fusion and motion‑preservation platform is set to dominate the growing musculoskeletal market, driven by its 19.7% revenue growth, robust 17% profit margin, and a free‑cash‑flow generation of $756 m. Our Bull Rankings model gives GMED a Quality‑Growth score of 79.2, with Growth as the strongest pillar, underscoring the durability of its compound‑rate earnings. The reverse‑DCF implies only ~3% FCF growth for the next decade—far below the 19.7% top‑line pace—meaning the market is already pricing in a very conservative outlook, leaving ample upside if the growth trajectory holds.
Moat. The company’s integrated spine portfolio—from traditional pedicle‑screw systems to total disc replacements—creates high switching costs for hospitals that must retrain staff and re‑qualify implants, locking in recurring revenue. Its FDA‑cleared biologic allografts and synthetic alternatives further deepen the product stickiness, giving GMED a defensible edge that competitors cannot replicate quickly without costly clinical trials.
Risk. At a forward P/E of 21.9, GMED trades at a premium that assumes sustained high‑margin growth; any slowdown in the 19.7% revenue acceleration or margin compression would expose the valuation gap. A modest beta of 0.95 masks the risk that a slowdown in elective spine procedures—driven by payer tightening or alternative therapies—could erode cash flow, and a breach of the 52‑week low ($54.15) would trigger a sell‑off. The bear case crystallizes if the reverse‑DCF’s 3% growth assumption becomes reality, capping upside at the consensus target.
Horizon. 1-3 yr $103.23 (analyst consensus (n=13)) — fundamentals + valuation re-rating. 5 yr $151.14 at ~12% CAGR — compounding case rests on the competitive position widening. 10 yr $224.21 if current growth sustains into durable earnings power.
21. META — Meta Platforms, Inc. · score 79.1
Internet Content & Information · price $545.83 · 1Y $754.14 · 5Y $1,104 · 10Y $1,638
FCF $41.0b A · Rev +27.7% A- · D/E 0.43 B+ · P/E 20.6x B · PEG 0.82 B+
Why now. Meta’s Family of Apps is exploding as advertisers chase the 27.7% YoY revenue growth and the platform’s 29.8% profit margin fuels a massive $41.0 B free‑cash‑flow engine, giving the stock a clear compounding driver. The FoA segment’s entrenched user base and expanding ad inventory keep the growth loop alive, and with a 26.1% ROE the cash returns are being reinvested at a premium. The thesis rests on the continuation of this high‑margin, high‑growth cash engine.
Moat. Meta’s moat lives in the network effects of Facebook and Instagram, where each additional user makes the platform more valuable to advertisers, creating a self‑reinforcing loop that competitors can’t duplicate quickly. The 26.1% ROE reflects pricing power derived from category leadership in social‑media advertising, while the massive data moat powers AI‑driven ad targeting that locks in high‑margin revenue.
Risk. The bears warn that the market is pricing in an aggressive 29% annual free‑cash‑flow growth via the reverse DCF, far above the realistic 27.7% revenue growth, and a P/E of 20.6 suggests the stock is already stretched. A slowdown in ad spend or a misstep in Reality Labs could erode the 29.8% margin, and the beta of 1.24 amplifies downside in a volatile market. A sustained drop in margin or a failure to meet the implied growth would trigger a re‑rating to a lower multiple.
Horizon. 1-3 yr $754.14 (analyst consensus (n=57)) — fundamentals + valuation re-rating. 5 yr $1,104 at ~15% CAGR — compounding case rests on the competitive position widening. 10 yr $1,638 if current growth sustains into durable earnings power.
22. CPAY — Corpay, Inc. · score 78.8
Software - Infrastructure · price $412.00 · 1Y $450.64 · 5Y $659.79 · 10Y $978.75
FCF $1.6b C+ · Rev +20.4% A- · D/E 2.75 D · P/E 25.0x B+ · PEG 0.93 B+
Why now. Corpay’s corporate payments platform is rapidly expanding its market share, driving 20.4% FY YoY revenue growth and delivering a 22.7% profit margin. The business’s ROE of 32.2% and a PEG of 0.93 signal that earnings are expanding faster than the market expects, while our Bull Rankings model flags a 78.8/100 quality‑growth score with Growth as the strongest pillar – confirming the durability of this compounding engine. The thesis hinges on continued adoption of its cross‑border and virtual‑card solutions, which should keep earnings compounding at double‑digit rates.
Moat. Corpay’s AP modernization and virtual‑card suite lock large enterprises into a unified spend‑management workflow, creating high switching costs and pricing power that underpins its 32.2% ROE. The integrated vehicle‑payment and lodging‑payment services deepen relationships across corporate travel budgets, making it difficult for rivals to replicate the breadth of data and compliance capabilities without substantial investment.
Risk. The stock trades at a forward P/E of 25, well above the sector median, and the Bull Rankings model’s reverse‑DCF implies only ~3% annual free‑cash‑flow growth – far below the 20.4% revenue expansion, meaning the market is already pricing in aggressive optimism. A slip in growth or a rise in the debt‑to‑equity ratio of 2.75 would force the valuation down, and any slowdown in corporate travel spend would directly hit the vehicle and lodging segments. A breach of the 52‑week low at $252.84 would confirm the bear case.
Horizon. 1-3 yr $450.64 (analyst consensus (n=14)) — fundamentals + valuation re-rating. 5 yr $659.79 at ~10% CAGR — compounding case rests on the competitive position widening. 10 yr $978.75 if current growth sustains into durable earnings power.
23. ACN — Accenture plc · score 78.4
Information Technology Services · price $181.35 · 1Y $179.11 · 5Y $262.23 · 10Y $389.00
FCF $12.6b A- · Rev +6.7% C+ · D/E 0.25 B · P/E 14.5x A- · PEG 1.33 B
Why now. Accenture’s AI‑driven intelligent platform services are now the engine of its next growth wave, feeding a 6.7% FY revenue growth while delivering a 10.7% profit margin and a robust $12.6B free cash flow. Our model’s Quality pillar (89) underscores the firm’s high‑margin, high‑return engine, and the 1‑yr analyst consensus of $179.11 signals near‑term upside as clients accelerate cloud and AI spend. The thesis rests on sustained compounding of AI‑enabled engagements that keep the revenue growth trajectory ahead of the market.
Moat. Accenture’s global delivery network and deep integration capabilities lock in large enterprise contracts for systems integration, security, and data‑AI services, creating switching costs that protect its pricing power and drive a 24.4% ROE. Its industry‑specific platforms, such as banking and health services, embed Accenture’s IP into core business processes, making it hard for rivals to replicate the scale and depth of expertise.
Risk. The stock trades at a forward P/E of 14.8, well above the sector average, and the Bull Rankings model’s reverse‑DCF implies a -8% annual FCF growth rate, a stark mismatch to the actual 6.7% revenue growth, suggesting the market has priced in overly optimistic cash‑flow expansion. A slowdown in AI spend or a rise in the debt‑to‑equity ratio beyond 0.25 would pressure margins and could trigger a re‑rating, confirming the bear case.
Horizon. 1-3 yr $179.11 (analyst consensus (n=25)) — fundamentals + valuation re-rating. 5 yr $262.23 at ~7% CAGR — compounding case rests on the competitive position widening. 10 yr $389.00 if current growth sustains into durable earnings power.
24. BSX — Boston Scientific Corporation · score 78.4
Medical Devices · price $49.37 · 1Y $62.69 · 5Y $91.78 · 10Y $136.16
FCF $3.6b B · Rev +13.5% B+ · D/E 0.50 B · P/E 20.0x B+ · PEG 0.75 A-
Why now. Boston Scientific’s growth engine is anchored in its Cardiovascular segment, where demand for minimally invasive stent and delivery systems is exploding – revenue is expanding at 13.5% YoY, profit margins sit at a healthy 17.5%, and free cash flow tops $3.6 B on a $73 B market cap, delivering a 5% FCF yield. Our Bull Rankings model gives BSX a Quality‑Growth score of 78.4, with Growth as the strongest pillar, underscoring the durability of this compounding revenue stream. The thesis rests on the continued rollout of single‑use duodenoscopes and SpyGlass platforms that lock in hospital spend and drive recurring sales.
Moat. BSX’s moat lives in its proprietary endoscopic and cardiovascular device platforms that require extensive clinical validation and hospital integration, creating high switching costs for surgeons and interventional cardiologists. The company’s 14.7% ROE reflects pricing power from category leadership in single‑use scopes and biliary stents, where competitors face steep regulatory and manufacturing barriers.
Risk. The bear case hinges on the steep discount to its 52‑week high – the stock trades at $50.37 versus a high of $109.5, implying a P/E of 20.4 that may be stretched if revenue growth stalls below the current 13.5% pace. A modest debt‑to‑equity of 0.5 limits financial flexibility, and any slowdown in adoption of its high‑margin endoluminal products could compress margins, confirming the downside if the price falls back toward the 52‑week low of $42.2.
Horizon. 1-3 yr $62.69 (analyst consensus (n=29)) — fundamentals + valuation re-rating. 5 yr $91.78 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $136.16 if current growth sustains into durable earnings power.
25. VEEV — Veeva Systems Inc. · score 77.8
Health Information Services · price $250.53 · 1Y $251.43 · 5Y $368.12 · 10Y $546.08
FCF $1.7b C+ · Rev +16.2% B+ · D/E 0.01 A- · P/E 44.3x C · PEG 1.13 B+
Why now. Health Information Services · market cap $40.7b. 19% off the 52-week high of $310.50. Revenue growing +16%, comfortably above the S&P median. 28 sell-side analysts rate this a Buy with a mean 1-yr target of $251.43 (implying +0% upside).
Moat. Net margin 28% sits well above the S&P median (~11%) — suggests structural pricing advantage or cost discipline competitors can't quickly close. ROE 13% meets the long-run market sustainable threshold — solid but not differentiated; the durability comes from elsewhere. FCF converts 177% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Trailing P/E 44x sits well above the S&P median (~20x) — multiple compression is a real risk if revenue growth decelerates. P/S 12.3x embeds aggressive forward growth — disappointing top-line guidance would compress the multiple hard.
Horizon. 1-3 yr $251.43 (analyst consensus (n=28)) — fundamentals + valuation re-rating. 5 yr $368.12 at ~8% CAGR — compounding case rests on the competitive position widening. 10 yr $546.08 if current growth sustains into durable earnings power.
26. WMG — Warner Music Group Corp. · score 77.2
Entertainment · price $27.10 · 1Y $36.88 · 5Y $46.56 · 10Y $59.72
FCF $836m C+ · Rev +12.9% B+ · D/E 4.53 D · P/E 21.7x B · PEG 0.49 A
Why now. Entertainment · market cap $14.2b. Down 23% from 52-week high of $35.42 — deep drawdown territory. Revenue growing +13%, comfortably above the S&P median. PEG 0.49 — paying under fair value for the growth rate. 17 sell-side analysts rate this a Buy with a mean 1-yr target of $36.88 (implying +36% upside).
Moat. ROE 79% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 124% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. D/E 4.53 is elevated — limits strategic flexibility and raises refinancing exposure if rates stay higher for longer.
Horizon. 1-3 yr $36.88 (analyst consensus (n=17)) — multiple re-rating thesis requires a catalyst. 5 yr $46.56 at ~11% CAGR — dividend + buyback compounding. 10 yr $59.72 if the moat survives secular pressure.
27. CCK — Crown Holdings, Inc. · score 75.4
Packaging & Containers · price $117.15 · 1Y $136.57 · 5Y $172.42 · 10Y $221.12
FCF $1.2b C+ · Rev +10.3% B · D/E 1.86 C+ · P/E 16.9x B+ · PEG 0.64 A-
Why now. Packaging & Containers · market cap $12.7b. 5% off the 52-week high of $122.91. Revenue growing +10%, comfortably above the S&P median. PEG 0.64 — paying under fair value for the growth rate. 14 sell-side analysts publish a mean 1-yr target of $136.57 (implying +17% upside).
Moat. ROE 27% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which. FCF converts 153% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $136.57 (analyst consensus (n=14)) — multiple re-rating thesis requires a catalyst. 5 yr $172.42 at ~8% CAGR — dividend + buyback compounding. 10 yr $221.12 if the moat survives secular pressure.
28. EME — EMCOR Group, Inc. · score 75.3
Engineering & Construction · price $787.39 · 1Y $1,033 · 5Y $1,304 · 10Y $1,673
FCF $1.2b C+ · Rev +18.9% B+ · D/E 0.13 A- · P/E 24.5x B+ · PEG 0.40 A
Why now. Engineering & Construction · market cap $34.7b. 17% off the 52-week high of $951.96. Revenue growing +19%, comfortably above the S&P median. PEG 0.40 — paying under fair value for the growth rate. 7 sell-side analysts rate this a Buy with a mean 1-yr target of $1,033 (implying +31% upside).
Moat. ROE 35% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $1,033 (analyst consensus (n=7)) — multiple re-rating thesis requires a catalyst. 5 yr $1,304 at ~11% CAGR — dividend + buyback compounding. 10 yr $1,673 if the moat survives secular pressure.
29. CF — CF Industries Holdings, Inc. · score 74.5
Agricultural Inputs · price $125.70 · 1Y $125.77 · 5Y $158.79 · 10Y $203.64
FCF $1.9b C+ · Rev +20.0% A- · D/E 0.41 B · P/E 9.3x A · PEG 0.40 A
Why now. Agricultural Inputs · market cap $19.0b. 11% off the 52-week high of $141.96. Revenue growing +20%, comfortably above the S&P median. PEG 0.40 — paying under fair value for the growth rate. 19 sell-side analysts rate this a Hold with a mean 1-yr target of $125.77 (implying +0% upside).
Moat. Net margin 32% is exceptional — pricing-power territory rare outside premium software, branded staples, and specialty pharma. ROE 43% — top-decile capital efficiency. Either pricing leverage, low capital intensity, or aggressive buybacks; the durability story depends on which.
Risk. Value re-rating depends on a catalyst. Without one — analyst day, divestiture, margin recovery, capital return — the stock can stay cheap on these multiples for years.
Horizon. 1-3 yr $125.77 (analyst consensus (n=19)) — multiple re-rating thesis requires a catalyst. 5 yr $158.79 at ~5% CAGR — dividend + buyback compounding. 10 yr $203.64 if the moat survives secular pressure.
30. YUMC — Yum China Holdings, Inc. · score 74.5
Restaurants · price $48.88 · 1Y $62.05 · 5Y $90.85 · 10Y $134.77
FCF $940m C+ · Rev +8.8% B · D/E 0.38 A- · P/E 17.9x B+ · PEG 1.19 B+
Why now. Restaurants · market cap $16.7b. 16% off the 52-week high of $58.39. 21 sell-side analysts rate this a Strong Buy with a mean 1-yr target of $62.05 (implying +27% upside).
Moat. ROE 18% sits above Buffett's preferred 15% threshold — the equity base is compounding at a rate the market struggles to discount accurately. FCF converts 96% of net income — earnings translate cleanly into cash, a sign that working capital and capex are well-disciplined.
Risk. Mature compounder — the risk is paying up for quality at a moment when growth is decelerating. Watch for sequential revenue + margin trends; the inflection from "compounder" to "ex-compounder" is hard to spot until the multiple already started compressing.
Horizon. 1-3 yr $62.05 (analyst consensus (n=21)) — fundamentals + valuation re-rating. 5 yr $90.85 at ~13% CAGR — compounding case rests on the competitive position widening. 10 yr $134.77 if current growth sustains into durable earnings power.
Methodology footnote
Every pick on this list comes out of the same quality-growth model — one 0–100 score blending quality, growth, and value — applied to every US-listed common stock with a market cap above $1B. Each pick's score breakdown is auditable from the home page — click the ticker on the rankings page to see exactly which grades produced the number. Not investment advice. See terms for full disclosures.